

CLAIMS

1. Transdermal therapeutic system having a backing layer, at least one nicotine-containing layer or zone, which may have pressure-sensitive adhesive properties, as well as a removable protective layer, characterized by a content of at least one essential oil extracted from a mint species, or at least one monoterpene ketone contained in these essential oils.

2. Transdermal therapeutic system according to claim 1, characterized in that the monoterpene ketone is one from the group of carvone, dihydrocarvone, menthone, isopulegone, isomenthone, neomenthone, neoisomenthone or piperitone.

3. Transdermal therapeutic system according to claim 2, characterized in that the monoterpene ketones are used as pure enantiomers or mixtures thereof.

4. Transdermal therapeutic system according to claim 1, characterized in that the essential oil is spearmint oil (*Oleum Menthae crispae*).

5. Transdermal therapeutic system according to one or more of the preceding claims, characterized in that the content of monoterpene ketone(s) in the nicotine-containing matrix is 0.1 to 5.0%-wt., preferably 0.5 to 2%-wt.

6. Process for masking an unpleasant smell, caused by a content of nicotine, of a transdermal therapeutic system, characterized in that at least one odour-improving substance is added to the nicotine-containing transdermal therapeutic system, said substance being an essential oil extract d from a mint species, or being a monoterpene

*Sub B
contd*

ketone contained in an essential oil extracted from a mint species.

7. Process according to claim 6, characterized in that the essential oil is peppermint oil (Oleum Menthae crispae).

8. Process according to claim 6, characterized in that the monoterpene ketone is one from the group of carvone, dihydrocarvone, menthone, isopulegone, isomenthone, neomenthone, neoisomenthone or piperitone.

9. Process according to claim 8, characterized in that the monoterpene ketone(s) are added to the nicotine-containing matrix preferably in a concentration of 0.1 to 5.0%-wt, particularly preferred in a concentration of 0.5 to 2%-wt..

10. Use of an essential oil extracted from a mint species and/or of a monoterpene ketone contained in an essential oil extracted from a mint species, for masking an unpleasant smell of a transdermal therapeutic system, said smell being caused by a content of nicotine in said transdermal therapeutic system.

11. Use according to claim 10, characterized in that the monoterpene ketone is one from the group of carvone, dihydrocarvone, menthone, isopulegone, isomenthone, neomenthone, neoisomenthone or piperitone

12. Use according to claim 11, characterized in that the monoterpene ketone(s) are added to the nicotine-containing matrix preferably in a concentration of 0.1 to 5.0%-wt, particularly preferred in a concentration of 0.5 to 2%-wt.

13. Us according to claim 10, characterized in that the
essential oil is peppermint oil (Oleum Menthae crispa).

add B² >